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MaPulmonary hypertension (PH) is common andmay result froma number of disorders, including left heart disease, lung disease,
and chronic thromboembolic disease. Pulmonary arterial hypertension (PAH) is an uncommon disease characterized by pro-
gressive remodeling of the distal pulmonary arteries, resulting in elevated pulmonary vascular resistance and, eventually, in
right ventricular failure. Over the past decades, knowledge of the basic pathobiology of PAH and its natural history, prognostic
indicators, and therapeutic options has exploded. A thorough evaluation of a patient is critical to correctly characterize the PH.
Cardiac studies, including echocardiography and right heart catheterization, are key elements in the assessment. Given the
multitude of treatment options currently available for PAH, assessment of risk and response to therapy is critical in long-term
management. This review also underscores unique situations, including perioperative management, intensive care unit
management, and pregnancy, and highlights the importance of collaborative care of the PAH patient through a multidisci-
plinary approach. (J Am Coll Cardiol 2015;65:1976–97) © 2015 by the American College of Cardiology Foundation.P ulmonary hypertension (PH) deﬁnes a groupof clinical conditions presenting with ab-normal elevation in the pulmonary circulation
pressure (1,2). The normal mean pulmonary artery
pressure (mPAP) at rest is 14  3.3 mm Hg, and the up-
per limit of normal is 20.6 mm Hg (3); nevertheless,
PH is deﬁned as an increase of mPAP $25 mm Hg at
rest, as assessed by right heart catheterization (4).
Over the past 2 decades, advances in the understand-
ing of basic mechanisms, clinical characteristics, and
treatment options have substantially changed our
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CLASSIFICATION
The recognition of subgroups of patients sharing
speciﬁc features has led to the most recent classiﬁ-
cation of PH (Table 1) (5). The current classiﬁcation
groups patients with similar pathological ﬁndings,
hemodynamic proﬁles, and management strategies.
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TABLE 1 Updated Classiﬁcation of PH*
1. Pulmonary arterial hypertension
1.1 Idiopathic PAH
1.2 Heritable PAH
1.2.1 BMPR2
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drug and toxin induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
10. Pulmonary veno-occlusive disease and/or pulmonary
capillary hemangiomatosis
10 0. Persistent PH of the newborn
2. PH due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inﬂow/outﬂow tract
obstruction and congenital cardiomyopathies
3. PH due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and
obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases
4. Chronic thromboembolic PH
5. PH with unclear multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia, myelo-
proliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis,
lymphangioleiomyomatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher
disease, thyroid disorders
5.4 Others: tumoral obstruction, ﬁbrosing mediastinitis,
chronic renal failure, segmental PH
*5th World Symposium on Pulmonary Hypertension, Nice, France, February 27 to
March 1, 2013. Changes since the last symposium are in bold.
BMPR 2 ¼ bone morphogenetic protein receptor type 2; CAV1 ¼ caveolin-1;
ENG ¼ endoglin; HIV ¼ human immunodeﬁciency virus; PAH ¼ pulmonary
arterial hypertension; PH ¼ pulmonary hypertension.
AB BR E V I A T I O N S
AND ACRONYM S
CHD = congenital heart disease
CTD = connective
tissue disease
IPAH = idiopathic pulmonary
hypertension
mPAP = mean pulmonary
artery pressure
PAH = pulmonary arterial
hypertension
PCWP = pulmonary capillary
wedge pressure
PH = pulmonary hypertension
PVR = pulmonary vascular
resistance
RV = right ventricle/ventricular
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1977evaluation, characterized by an mPAP $25 mm Hg
with normal pulmonary artery occlusion pressure
(i.e., pulmonary capillary wedge pressure [PCWP]
#15 mm Hg) and pulmonary vascular resistance (PVR)
above 3 Wood units, in the absence of pulmonary
parenchymal or thromboembolic disease. As shown in
Table 1, PAH may occur in isolation or in association
with several clinical conditions.
Id iopath ic and her i tab le PAH. Although idiopathic
pulmonary arterial hypertension (IPAH) might repre-
sent the most studied form of PAH, it corresponds to a
rare presentation in which no family history of PAH or
associated risk factor is present. Therefore, IPAH is
only diagnosed after extensive investigation ruling
out alternative diagnoses (4).
Heritable forms of PAH include those with identi-
ﬁed gene mutations and familial cases with orwithout mutations. Up to 80% of familial
cases of PAH have been linked to germline
mutations in the gene coding for the bone
morphogenetic protein receptor type II
(BMPR2), a member of the transforming
growth factor (TGF)-b signaling family (6).
BMPR2 mutations have also been detected in
around 20% of apparently idiopathic cases
without a family history of PAH (7). Other
mutations in genes from the TGF-b family are
also known to be associated with particular
PAH presentations, such as comorbid hered-
itary hemorrhagic telangiectasia (ACVRL1,
Endoglin) (8).
Recently, mutations in the novel PAH-
associated genes Caveolin 1 and KCNK3 have
been described. Caveolin 1 (9) and KCNK3 (10)
are not closely related to the TGF-b family, thereby
providing new and different insights in terms of po-
tential pathophysiological mechanisms and thera-
peutic targets.
Drug- and tox in- induced PAH. A signiﬁcant num-
ber of substances have been described as poten-
tially associated with the development of PAH.
Aminorex and fenﬂuramine derivatives are clear
examples where a robust association between drug
exposure and PAH has been demonstrated through
the analysis of outbreaks of PAH in the 1960s and
1990s (11,12). More recently, benﬂuorex, a benzoate
ester that shares structural and pharmacologic char-
acteristics with dexfenﬂuramine and fenﬂuramine,
has also been associated with the development of
PAH (13). Among other classes of drugs that may be
linked to the development of PAH, dasatinib, a tyro-
sine kinase inhibitor, gained particular attention after
a case series of drug-induced PAH was reported in
chronic myelogenous leukemia patients (14). Type I
interferons have also been linked to an increased risk
of developing PAH (15).
PAH associated with connective tissue diseases. One
of the most important forms of PAH is connective
tissue disease (CTD)-associated PAH. CTD-associated
PAH accounts for 15% to 25% of all PAH cases in
worldwide registries, with systemic sclerosis and
systemic lupus erythematosus as the leading causes
(16,17). These patients have a particularly poor prog-
nosis, with an estimated 30% 1-year mortality,
compared to 15% in IPAH. It was recently suggested
that implementation of a systematic screening pro-
gram to allow earlier diagnosis and intervention
might result in better long-term outcomes for this
subgroup of PAH patients (18,19). Cases of reversible
PAH have been reported in PAH patients with sys-
temic lupus erythematosus and mixed CTD.
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1978PAH assoc iated with human immunodeﬁc iency
v i rus . Patients with human immunodeﬁciency virus
(HIV) are at increased risk of developing PAH. The
prevalence of PAH in this group is estimated to
be 0.5% (20,21), with clinical and hemodynamic pre-
sentation very similar to IPAH. Prognosis of HIV-
associated PAH has improved in recent years; in the
REVEAL (Registry to Evaluate Early And Long-term
PAH Disease Management) registry, the survival of
HIV-associated PAH was 93% at 1 year and 75% at 3
years (22). Cases of reversible PAH have been re-
ported in HIV patients treated with PAH drugs and
highly-active antiretroviral drugs (22).
PAH assoc iated with porta l hypertens ion . About
6% of patients with portal hypertension develop PAH,
independent of the severity of the liver disease,
although the long-term prognosis of these patients is
related to the severity of both the liver and pulmo-
nary vascular disease. Portopulmonary hypertension
represents an important problem for liver trans-
plantation programs because its presence is related to
increased mortality during and after the procedure,
particularly if the mPAP is >35 mm Hg. The prognosis
in portopulmonary hypertension is worse than in
IPAH; recently reported data suggest a 3-year survival
of 40% (23).
PAH assoc iated with congeni ta l heart d iseases .
Due to the improvement in the management of
congenital heart diseases (CHDs), more children with
CHD survive to adulthood. Because about 10% of
adults with CHD develop PAH (24), CHD-associated
PAH is a signiﬁcant subgroup in PH referral centers.
PAH assoc iated with sch i stosomias i s . PH repre-
sents one of the most severe complications of chronic
schistosomiasis (Sch), an infectious disease caused by
parasitic trematode worms. A PH screening program
identiﬁed a 4.6% prevalence of PAH among patients
diagnosed with hepatosplenic schistosomiasis man-
soni (25), highlighting the relevance of this form of
PAH, considering the worldwide distribution of the
infection. A recent registry demonstrated that Sch-
PAH might be responsible for about 20% of all
newly-diagnosed PAH cases in endemic countries.
The clinical and histopathological similarities be-
tween Sch-PAH and IPAH have been recently
described (26), although Sch-PAH apparently has a
more benign clinical course with a 3-year mortality of
about 15% (26). A recent case series also suggested
that these patients might have a beneﬁcial response
to PAH targeted therapies (27).
Pulmonary veno-occ lus ive d isease , pu lmonary
cap i l la ry hemangiomatos i s , and pers i s tent PH
of the newborn . Pulmonary veno-occlusive disease(PVOD) and pulmonary capillary hemangiomatosis,
rare variants within the same spectrum of disease,
share some similarities with PAH, although with re-
markable differences in presentation, mainly with
respect to chest computed tomography ﬁndings,
causal homozygous EIF2AK4 mutations in heritable
cases, and clinical course (28,29). These entities
remain closer to the PAH spectrum of disease than to
any other PH group and, thus, are classiﬁed as 10. Due
to numerous differences with all other forms of PAH,
persistent PH of the newborn has also been with-
drawn from the PAH group and is classiﬁed as 10 0 (5).
GROUP 2: PH DUE TO LEFT HEART DISEASE. This
group encompasses the most frequent form of PH. In
these patients, PH is a consequence of the elevated
ﬁlling pressures of the left heart chambers trans-
mitted backward to the pulmonary circulation. In this
setting, PVR is usually normal, as is the gradient be-
tween the mPAP and the PCWP (transpulmonary
gradient; <12 mm Hg) and the gradient between the
diastolic pulmonary artery pressure and the PCWP
(diastolic pressure gradient; <5 to 7 mm Hg). Never-
theless, in a subgroup of patients, a pre-capillary
component might also be present, characterizing a
mixed hemodynamic pattern (combined pre- and
post-capillary PH) (30). Further studies are necessary
to assess the potential beneﬁts and risks of PAH-
speciﬁc therapy in this group.
GROUP 3: PH DUE TO LUNG DISEASES AND/OR
HYPOXIA. This group comprises patients with par-
enchymal lung diseases or other causes of hypoxia
(e.g., obstructive sleep apnea) in whom the presence
of PH is considered directly related to these under-
lying diseases. Thus, all forms of ventilatory distur-
bances are considered: obstructive, restrictive, and
the combination of both patterns. In particular, the
presence of a mixed pattern (obstructive and restric-
tive), as in the coexistence of pulmonary ﬁbrosis and
emphysema, results in an increased prevalence of PH.
Thus far, no signiﬁcant beneﬁt from the use of tar-
geted PAH therapies has been demonstrated in this
group.
GROUP 4: CHRONIC THROMBOEMBOLIC PULMONARY
HYPERTENSION. Up to 4% of all patients with acute
pulmonary embolism may ultimately develop chronic
thromboembolic pulmonary hypertension (CTEPH),
which is considered a curable form of PH when per-
forming a pulmonary endarterectomy is possible.
Operability depends on several factors, including
the pattern of vascular obstruction, hemodynamic
severity, and experience of the referral center, among
others. More recently, PAH-speciﬁc medical therapy
and balloon pulmonary angioplasty have been used
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1979for patients who were not candidates for surgery or
who remained with residual PH after surgery with
beneﬁcial results.
GROUP 5: PH WITH UNCLEAR OR MULTIFACTORIAL
MECHANISMS. Included in this group are numerous
forms of PH in which multiple pathophysiological
mechanisms might be implicated in the elevation in
pulmonary vascular pressures. Given the heteroge-
neity of this group, further research is necessary to
better establish appropriate diagnostic criteria and
management strategies for each speciﬁc subform.
PATHOLOGY AND PATHOBIOLOGY OF PAH
In PAH, pulmonary vascular lesions predominantly
affect the small pulmonary arteries (diameter<500 mm).
A wide array of changes can all occur in PAH,
ranging from medial hypertrophy, intimal prolifer-
ative and ﬁbrotic changes (concentric, eccentric),
adventitial thickening with moderate perivascular
inﬂammatory inﬁltrates (which may be more pro-
nounced and organized in tertiary lymphoid tissue),
complex lesions (plexiform, dilated lesions), and
thrombotic lesions (31–33). In contrast to PVOD,
pulmonary veins are less affected in PAH (31).
Figure 1 highlights some key pathobiological abnor-
malities in PAH.
Vasoconstriction/vasodilation imbalance, throm-
bosis, cell proliferation, and remodeling of the
pulmonary arterial walls contribute to PAH pathobi-
ology (32,33). Several cell types play a role in the
disease, including endothelial cells, smooth muscle
cells, pericytes, myoﬁbroblasts, inﬂammatory cells
(macrophages, dendritic cells, mast cells, T and B
lymphocytes), and platelets (32–35). Pulmonary
vasoconstriction has long been regarded as an early
event, and excessive pulmonary vasoconstriction has
been related to abnormal function or expression of
potassium-channels and to endothelial dysfunction
characterized by reduced production of vasodilators
(nitric oxide and prostacyclin) and overproduction of
vasoconstrictors (endothelin-1) (32). These factors
will increase pulmonary vascular tone and favor
remodeling, and therefore represent logical pharma-
cological targets. Other mediators are also believed to
play an important role in subsets of PAH patients,
including proinﬂammatory cytokines (interleukin-1
and -6, tumor necrosis factor a), chemokines, sero-
tonin, angiopoietins, bone morphogenetic proteins
(BMPs), growth factors, and members of the TGF-b
superfamily (32–36). Proteolysis of the extracellular
matrix and autoimmunity are also likely to contribute
to disease pathobiology. The key role of the TGF-b
superfamily in pulmonary vascular remodeling hasbeen highlighted by cases of heritable PAH due to
germline mutations of BMPR2, ACVRL1, and Endoglin
(37). The products of these genes are involved in the
regulation of growth, differentiation, and apoptosis
of pulmonary artery endothelial and smooth muscle
cells. Idiopathic and heritable PAH affect twice as
many females as males, emphasizing the likely role
of additional factors in the pathobiological mecha-
nisms leading to PAH, including sexual hormones and
pregnancy (37).
NATURAL HISTORY OF PAH,
LESSONS FROM REGISTRIES
Until the end of the last century, PAH was a true
orphan disease, that is, a condition affecting a few
individuals and overlooked by the medical and
pharmaceutical world. Although rare, a number of
important recent ﬁndings have signiﬁcantly im-
proved our understanding of PAH. In 1973, the World
Health Organization sponsored the ﬁrst international
conference on a condition that was then named
“primary” PH (currently idiopathic, heritable, and
drug-induced PAH) in Geneva, Switzerland. The
marked increase in the incidence of the disease in
patients who had used an anorectic pill (aminorex
fumarate) explained, at least in part, the medical
world’s interest in this devastating condition. The
experts attending this conference recommended
collection of patient information into registry data-
bases to enable characterization of the disease in
terms of demographics, clinical presentations, and
outcomes. In 1981, the National Heart, Lung, and
Blood Institute of the National Institutes of Health
(NIH) launched the ﬁrst national registry of patients
with so-called “primary” PH. By the time the reg-
istry closed in 1987, only 187 patients (mean age
36  15 years) had been recruited from 32 centers (38).
These patients were described and followed for up
to 5 years, leading to major advances in the under-
standing of the natural history of the disease, which
had a poor prognosis with a median survival of 2.8
years following diagnosis. More recently, several
registries have described the characteristics and sur-
vival of PAH patients in the modern management era.
In the early 2000s, the French registry described
consecutive adult patients from 17 expert centers.
Within a year, 674 patients (age 50  15 years) were
entered in this registry (16). The estimates of preva-
lence and incidence of PAH were 15.0 cases/million
and 2.4 cases/million per year, respectively. Idio-
pathic, familial, and anorexigen-induced PAH ac-
counted for around one-half of the cases (39.2%,
3.9%, and 9.5%, respectively); the other one-half
FIGURE 1 Pathobiology of PAH
(A) Pulmonary vasoconstriction has long been regarded as an early event, and excessive pulmonary vasoconstriction has been related to abnormal function or expression
of potassium-channels and to endothelial dysfunction characterized by reduced production of vasodilators (nitric oxide and prostacyclin), along with overproduction of
vasoconstrictors (endothelin-1). Recently, a novel channelopathy due to KCNK3mutation has been identiﬁed in heritable cases of pulmonary arterial hypertension (PAH),
which may also favor vasoconstriction. (B) Pulmonary vascular remodeling and inﬂammation: proinﬂammatory cytokines (interleukin-1 and -6, tumor necrosis factor a),
chemokines, serotonin, angiopoietins, bone morphogenetic proteins (BMPs), growth factors, and members of the transforming growth factor (TGF)b superfamily, but
also proteolysis of the extracellular matrix and autoimmunity, are key triggers in smooth muscle cells, endothelial cells, ﬁbroblasts and pericytes proliferation and
migration. Proteolysis of the extracellular matrix and autoimmunity (as evidenced here by perivascular lymphoid neogenesis) are also likely to initiate or perpetuate
arterial remodeling. (C) Endothelial dysfunction, proliferation, and resistance to apoptosis, triggered by aberrant production of angiogenic growth factors (FGF2, PDGF,
VEGF), and genetic abnormalities in TGF-b signaling (BMPR2, ACVRL1/ALK1, endoglin, SMADs), and in endothelial scaffolding protein (Caveolin-1), may favor aberrant
angiogenesis (and subsequent increased vascular resistance) in PAH that is best exempliﬁed by plexiform lesions. (D) Thrombotic arteriopathy, a highly prevalent
pathological pattern of PAH, is an important pathophysiological feature of the disorder. Indeed, endothelial dysfunction leads to local thrombosis in PAH. Prepared from
original drawings courtesy of Frédéric Perros, PhD, Inserm UMR_S 999, Université Paris-Sud, Hôpital Marie Lannelongue Le Plessis Robinson, France.
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1980corresponded to patients with well-characterized
comorbidities (diagnosis of CTD, CHD, portal hyper-
tension, or HIV infection was made in 15.3%, 11.3%,
10.4%, and 6.2% of the population, respectively).
Most patients had advanced functional impairment at
the time of diagnosis, with 75% of patients in New
York Heart Association (NYHA) functional class III
or IV and a reduced 6-min walk distance (6MWD) of
329  109 m. Severe hemodynamic impairment was
present, with an mPAP of 55  15 mm Hg, cardiac
index of 2.5  0.8 l/min/m2, and PVR index of 20.5 
10.2 Wood unit index, respectively. Delay betweensymptom onset (mainly dyspnea on exercise) and
PAH diagnosis was 27 months, similar to that
observed in the NIH Registry, emphasizing the need
for better PAH awareness and diagnostic strategy.
Patients were then followed for 3 years and survival
rates were analyzed. For incident (newly diagnosed)
idiopathic, familial, and anorexigen-induced PAH,
estimated survival at 1, 2, and 3 years was 85.7% (95%
conﬁdence interval [CI]: 76.5% to 94.9%), 69.6% (95%
CI: 57.6% to 81.6%), and 54.9% (95% CI: 41.8% to
68.0%), respectively (39). This registry demonstrated
that PAH was still detected late in the course of the
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1981disease in the modern management era, with a ma-
jority of patients displaying severe functional and
hemodynamic compromise.
An important objective of registries is to identify
patient characteristics that predict outcome. The NIH
Registry was the ﬁrst to develop a prognostic equa-
tion. Use of this equation in the current treatment era
has limitations, as it provides information only on
the natural history of untreated idiopathic/heritable
PAH. More recent registries have identiﬁed predictors
of outcome that show similarities between studies,
including disease etiology, patient sex, functional
impairment, and factors reﬂective of right heart
function. In the French registry, individual survival
analysis identiﬁed the following factors as signiﬁ-
cantly and positively associated with survival: female
sex; NYHA functional class I/II; greater 6MWD; lower
right atrial pressure; and higher cardiac output.
Multivariable analysis showed that female sex and
having a greater 6MWD and higher cardiac output
were jointly signiﬁcantly associated with improved
survival. Both the French and U.S. REVEAL equations
have shown strong predictive power when cross-
validated in matched patients from the U.S. REVEAL
and French registries, respectively (39,40).
DIAGNOSTIC EVALUATION OF THE PATIENT
WITH SUSPECTED PH
The diagnosis of PAH, especially in those without
apparent risk factors, requires a high index of suspi-
cion because typical presenting symptoms such as
dyspnea, exercise intolerance, and fatigue are non-
speciﬁc (1,2,4). In contrast, signs of PH, such as
elevated pulmonary artery systolic pressure (PASP)
and enlarged pulmonary arteries, are often encoun-
tered on imaging tests, such as Doppler echocardiog-
raphy and chest computed tomography, respectively.
In these patients, PAH, which is much more rare than
other causes of PH (such as left heart disease and
chronic lung disease), is unlikely. Thus, clinicians
must be able to both recognize clues regarding the
presence of PAH (to avoid missing the diagnosis of
this rare disease) and correctly determine the etiology
and type of PH when found incidentally on routine
testing (to avoid incorrect and potentially harmful
treatment).
Although the history and physical examination are
not always deﬁnitive, much information can be
gathered from this initial step. Clues in the clinical
history that increase the likelihood of PH include:
exertional lightheadedness or syncope; symptoms of
right heart failure, such as leg swelling, abdominal
distension, and anorexia; and the presence of PAHrisk factors, such as portal hypertension, CTD, CHD,
HIV, exposure to drugs/toxins known to induce PAH
(e.g., anorexigens), and a family history of PAH (4,17).
Physical examination ﬁndings sometimes observed in
PH and right ventricular (RV) dysfunction include: an
elevated jugular venous pressure with prominent A
waves (due to increased RV stiffness) and V waves
(due to tricuspid regurgitation [TR]); Kussmaul’s sign
(increased jugular venous pressure with inspiration,
due to a noncompliant RV or signiﬁcant TR); an RV
lift; a loud P2; right-sided S3 and/or S4; murmur of TR;
and signs of right heart failure (e.g., hepatomegaly,
ascites, and peripheral edema) (2).
Electrocardiographic signs of PH include RV hy-
pertrophy with strain pattern (increased R-wave
amplitude with ST-segment depression and T-wave
inversion in the precordial leads) and right atrial
enlargement (increased P-wave amplitude in leads II
and V1). The right atrium is often quite enlarged in
severe PAH and can mimic left atrial enlargement in
lead V1 (terminal negative deﬂection of the P-wave >1
small box), despite the presence of a small and
underﬁlled left atrium. On chest radiography, loss of
the retrosternal space on the lateral view (a sign of RV
enlargement), enlarged central pulmonary arteries,
and peripheral pruning can occur in PAH (1,2).
ECHOCARDIOGRAPHY. Comprehensive echocardi-
ography, with Doppler and tissue Doppler imaging,
is essential for screening and initial noninvasive
assessment of PH (41). Besides evaluating for possible
PH, the echocardiogram can evaluate for the cause of
PH (e.g., left heart disease lesions, agitated saline
bubble study to evaluate for shunt lesions). Although
clinicians are often focused on the PASP when eval-
uating patients with PH, it is just as critical to eval-
uate the right heart on echocardiography because of
the pitfalls of echocardiographic PASP assessment,
which have been reviewed previously (41). Table 2
displays a checklist of items to remember when
evaluating the echocardiogram in a patient with
known or suspected PH.
INVASIVE HEMODYNAMIC TESTING. Cardiac cathe-
terization is an essential step in the diagnosis of PH,
particularly PAH, and should be performed prior to
the initiation of PAH-speciﬁc therapy (1,2,4). When
performed at experienced centers, the risk of major
complications from right heart catheterization is low
(42). Nevertheless, invasive hemodynamic testing
requires careful technique to avoid potential pitfalls.
Standard good clinical practices, such as ensuring
proper zeroing of pressure transducers, measuring
pressures (particularly PCWP) at end-expiration, and
being cognizant of artifacts in the hemodynamic
TABLE 2 Checklist for the Echocardiographic Evaluation of PH
Completed? Action Item Notes
☐ Record estimated PASP  Underestimated when Doppler beam alignment is poor or when TR jet is minimal
 Overestimated in patients with signiﬁcant anemia or in some cases of agitated saline-enhanced TR jet on
continuous wave Doppler (due to feathering)
 Assumes absence of pulmonic stenosis
 Echocardiographic PASP does not equal mean PA pressure (deﬁnition of PH per guidelines is on the basis of
invasive hemodynamics: mean PA pressure $25 mm Hg)
☐ Evaluate RV size and function  Signs of RV enlargement (apical 4-chamber view): RV shares apex with LV; RV bigger than LV; RV basal diameter
>4.2 cm
 RV hypertrophy (subcostal view): RV end-diastolic wall thickness >5 mm
 RV systolic dysfunction: RV fractional area change <35%; TAPSE <1.6 cm; RV tissue Doppler s0 velocity <10 cm/s
at base of the RV free wall (tricuspid annulus)
 Septal ﬂattening: in systole ¼ RV pressure overload and in diastole ¼ RV volume overload
☐ Evaluate for signs of elevated PVR  RVOT notching on pulse-wave Doppler proﬁle is a sign of elevated PVR
 Peak TR velocity (m/s)/RVOT VTI (cm) <0.18: unlikely PVR is elevated
☐ Estimate volume status  Use size and collapsibility of IVC (during sniff maneuver) to determine RA pressure
 Hepatic vein ﬂow: systolic ﬂow reversal can be a sign of severe TR, RV overload, and/or increased RV stiffness
 Signs of RA overload/enlargement: RA area >18 cm2; interatrial septum bows from right to left
☐ Evaluate severity of TR  Features suggestive of severe TR include dense TR jet on continuous-wave Doppler, V-wave cutoff sign; and
systolic ﬂow reversal on hepatic vein pulse-wave Doppler imaging
☐ Evaluate for pericardial effusion  In patients with PAH, the presence of a pericardial effusion ¼ poor prognostic sign
☐ Evaluate for causes of PH (left heart
disease, shunt lesions)
 Left heart disease: look for overt LV systolic dysfunction, grade 2 or worse diastolic dysfunction, severe aortic or
mitral valvular disease, and less common abnormalities of the left heart (e.g., hypertrophic cardiomyopathy, cor
triatriatum)
 Shunt lesions: perform agitated saline bubble study
☐ Differentiate PAH from PVH  Signs favoring PVH: LA enlargement (LA size >RA size); interatrial septum bows from left to right; E/A ratio >1.2;
E/e0 (lateral) > 11; lateral e0 <8 cm/s;
 In patients with signiﬁcantly elevated PASP at rest: grade 1 diastolic dysfunction pattern (E/A ratio <0.8) favors
PAH diagnosis because of underﬁlled LA and decreased LV compliance due to RV/LV interaction (extrinsic
compression of LV by RV).
 See also Figure 1
IVC ¼ inferior vena cava; LA ¼ left atrial/atrium; LV ¼ left ventricular/ventricle; PA ¼ pulmonary artery; PAH ¼ pulmonary arterial hypertension PASP ¼ pulmonary artery systolic pressure; PH ¼ pulmonary
hypertension; PVH ¼ pulmonary vascular hypertension; PVR ¼ pulmonary vascular resistance; RA ¼ right atrial/atrium; RV ¼ right ventricular/ventricle; RVOT ¼ right ventricular outﬂow tract; TAPSE ¼
tricuspid annular plane systolic excursion; TR ¼ tricuspid regurgitation; VTI ¼ velocity-time integral.
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1982tracings (e.g., overshoot in the pressure tracing due to
an air bubble in the catheter, whip artifact due to
catheter movement) are essential for making the
correct diagnosis in patients with suspected or known
PH. In addition, because PCWP is so important for
differentiating PAH from pulmonary venous hyper-
tension (PVH), special care should be taken to ensure
that the PCWP measurement is accurate, including
ﬂuoroscopic conﬁrmation that the pulmonary artery
(PA) catheter is in the PCWP position, and that PCWP
hemodynamic waveforms are appropriate. If the ac-
curacy is in doubt, or if the PCWP value does not ﬁt
with the rest of the clinical picture, left ventricular
(LV) end-diastolic pressure should be measured.
DYNAMIC TESTING DURING INVASIVE HEMODYNAMIC
STUDIES. Acute pulmonary vasodilator testing is
indicated in PAH patients with idiopathic, heritable,
or anorexigen-induced PAH. A variety of pulmonary
vasodilators can be used, with inhaled nitric oxide
(iNO) used most commonly (43). Pulmonary vasodi-
lator testing helps to determine who is most likely to
respond to calcium-channel blocker therapy and
also provides prognostic information. A positiveresponse to pulmonary vasodilator testing should
include all of the following: 1) decrease in mPAP
to #40 mm Hg; 2) decrease of at least 10 mm Hg in
mPAP; and 3) unchanged or increased cardiac output
(43). It is important to note that a lack of acute pul-
monary vasodilator response does not signify a
“nonresponder” to PAH therapies. Most PAH patients
will not have a positive response to a pulmonary
vasodilator challenge; however, many of these pa-
tients will respond to long-term selective PAH-speciﬁc
therapy (see later section “Therapy for PAH”). Pulmo-
nary vasodilator challenge with agents such as iNO,
adenosine, and prostacyclins should not be per-
formed in patients with evidence of signiﬁcant PVH
(e.g., PCWP >18 to 20 mm Hg). Furthermore, although
pulmonary vasodilator testing has been used com-
monly in patients with “associated-PAH” such as HIV,
CTD, CHD, and portopulmonary hypertension, there
is less rigorous data supporting its use in these pa-
tients. There is no data supporting the use of vasodi-
lator testing or calcium-channel blockers in patients
with PH other than PAH.
Exercise testing can be very helpful in the assess-
ment of patients with suspected or known PH because
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1983most symptoms occur with exertion. Although the
diagnosis of “exercise-PH” is no longer recognized in
guidelines statements, exercise can help evaluate for
PVH. Given the ability to accurately document the
exercise load, we prefer to use a supine or upright
ergometer (instead of arm exercises) for exercise he-
modynamic testing. In patients with PVH due to heart
failure with preserved left ventricular ejection frac-
tion (HFpEF), low-level exercise (25 W on a supine
ergometer) typically results in signiﬁcant elevations
in PCWP (e.g., >20 to 25 mm Hg), and mPAP and
PCWP will rise in parallel with exercise-induced in-
creases in cardiac output (44). In patients with PAH,
there will be minimal rise in the PCWP during exer-
cise, whereas mPAP will rise, and the rise will be
much steeper than the rise in PCWP.
Volume challenge during invasive hemodynamic
testing can also be helpful in the diagnosis and man-
agement of PH. Typically, 10 ml/kg of warmed saline
can be infused intravenously over 10 min in patients if
there is still a suspicion of PAH or PVH, but the base-
line hemodynamic data is insufﬁcient for the diag-
nosis. Fluid challenge can be safely administered if
the patient being evaluated has a resting right atrial
pressure <10 mm Hg and mPAP <25 mm Hg, and may
be particularly helpful if cardiac output is low-normal
or decreased (e.g., cardiac index <2.5 to 3.0 l/min/m2).
In these patients, signs of PAH include a rise in
mPAP $25 mm Hg while PCWP remains #15 mm Hg.
Additional evidence suggestive of the diagnosis after
ﬂuid challenge are: 1) a reduction or no rise in cardiac
output; and 2) rise in RA pressure greater than the rise
in PCWP. Passive leg raise alone can also serve as a
volume challenge. If PCWP rises signiﬁcantly (to >20
mm Hg) with passive leg raise, it is likely that the
patient has PVH (44). Alternatively, if PCWP changes
little, but RA pressure increases to >15 mm Hg and
mPAP rises to >25 mm Hg with minimal change in
cardiac output, PAH may be present.
It is important to note that there is insufﬁcient
controlled data to provide ﬁrm guidelines on invasive
hemodynamic pressure cutoffs for post-exercise or
-volume challenge diagnosis of PAH. Thus, the
aforementioned post-exercise and -ﬂuid challenge
hemodynamic criteria for the presence of possible
PAH are rough estimates. Clinicians must integrate
the clinical information, echocardiographic ﬁndings,
and invasive hemodynamic data (pre- and post-
challenge) to make an accurate diagnosis.
DIFFERENTIATION OF PAH FROM PVH. In clinical
practice, differentiating PAH from PVH can be chal-
lenging. Given the very high prevalence of left heart
disease, it is important to try to determinenoninvasively the type of PH because invasive he-
modynamic testing can sometimes be avoided if it is
clear that the etiology of PH is left heart disease. In
some patients, such as those with heart failure with
reduced LV ejection fraction or severe aortic or mitral
valve disease, the diagnosis of PVH (Group 2) is usu-
ally straightforward. However, many patients who
are evaluated for PH have a normal LV ejection frac-
tion and no severe valvular lesions. In these patients,
differentiating PAH from PVH hypertension can be
challenging. Furthermore, some patients with PVH
may have superimposed PAH (the so-called combined
pre- and post-capillary PH), which adds additional
diagnostic complexities.
The clinical history can be helpful in differ-
entiating PAH from PVH. Thenappan et al. (45)
demonstrated that advanced age, the presence of
comorbidities such as systemic hypertension and
coronary artery disease, the absence of right atrial
enlargement, higher aortic systolic pressure, higher
mean right atrial pressure, and higher cardiac output
were the best variables to help differentiate
PH-HFpEF (due to PVH) from PAH.
Figure 2 displays helpful criteria on echocardiog-
raphy and invasive hemodynamic testing for the dif-
ferentiation of PAH versus PVH and for the diagnosis
of combined pre- and post-capillary PH, such as that
which occurs in patients with HFpEF with super-
imposed precapillary PH. In a study of 44 patients
with PH, Willens et al. (46) compared patients with
PAH (n ¼ 24) to those with PVH (n ¼ 20) and found
that the E/A and lateral E/e0 ratios were the 2 most
helpful echocardiographic parameters in differenti-
ating between types of PH: lateral E/e0 >9.2 had a
sensitivity of 95% and speciﬁcity of 96%; E/A ratio
>1.7 had a sensitivity of 75% and speciﬁcity of 91%.
Crawley et al. (47) used cardiac magnetic resonance
(CMR) in a similar study (n ¼ 37 with IPAH, n ¼ 21 with
PH-HFpEF, and n ¼ 23 without PH) and found that left
atrial volume was the best parameter for differenti-
ating PAH from PVH.
Invasive hemodynamic testing is the gold stan-
dard for differentiating PAH from PVH. In patients
with invasively-documented PH (mPAP $25 mm Hg),
PH consensus statements recommend the use of a
partition value of PCWP #15 mm Hg (for diagnosis of
PAH) versus PCWP >15 mm Hg for diagnosis of PVH
(1,2,4). However, the diagnosis of PVH with super-
imposed precapillary PH can be challenging. Some
patients with PVH, particularly those with HFpEF,
will have a high PA systolic pressure that drives
mPAP elevation and can result in elevated trans-
pulmonary gradient (mPAP-PCWP) and PVR. Because
these patients do not necessarily have superimposed
FIGURE 2 PAH Versus PVH: Echocardiographic and Invasive Hemodynamic Differentiation
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(Left) Prototypical echocardiographic and invasive hemodynamic ﬁndings from a patient with PAH. The RA and RV are severely enlarged, and the LV and LA are small and
underﬁlled. The interatrial septum bows from right to left. On mitral inﬂow, E/A ratio <1 because of underﬁlling of the LA and decreased compliance of the LV due to
extrinsic compression from the enlarged RV. The lateral e0 velocity and lateral E/e0 ratio are normal (<8) suggesting normal LV relaxation and ﬁlling pressures. There is
notching in the RV outﬂow tract proﬁle on pulse-wave Doppler imaging due to increased PA stiffness. PCWP is normal and the PADP-PCWP gradient is severely increased.
(Right) Prototypical echocardiographic and invasive hemodynamic ﬁndings from a patient with PVH. The LA is enlarged and the interatrial septum bows from left to
right. On mitral inﬂow, E/A ratio >1, lateral e0 velocity is reduced, and lateral E/e0 ratio is increased, suggestive of grade 2 diastolic dysfunction with impaired LV
relaxation and elevated LV ﬁlling pressures. There is no notching in the RV outﬂow tract proﬁle. PCWP is elevated, and there is no gradient between the PADP and PCWP.
Note that although the RV in the right panel is not enlarged, RV enlargement and dysfunction can be present in patients with isolated PVH. (Upper middle) Parameters
helpful for differentiating PAH from PVH on echocardiography and invasive hemodynamic testing. (Lower middle) Invasive hemodynamic ﬁndings in a patient with
combined pre- and post-capillary PH (elevated PCWP and PADP-PCWP gradient). It should be noted that the most challenging patients are in this middle zone (combined
pre- and post-capillary PH), with echocardiographic ﬁndings that lie in the middle of the prototypical examples of PAH and PVH shown here. In these patients, careful
evaluation of the echocardiogram and invasive hemodynamics will be necessary for an accurate diagnosis. E/A ¼ ratio of early to late (atrial) mitral inﬂow velocities; E/
e0 ¼ ratio of early mitral inﬂow velocity to early diastolic mitral annular tissue velocity; CO ¼ cardiac output; LA ¼ left atrial; mPAP ¼ mean pulmonary arterial pressure;
PADP ¼ pulmonary artery diastolic pressure; PAH ¼ pulmonary arterial hypertension; PCWP ¼ pulmonary capillary wedge pressure; PH ¼ pulmonary hypertension;
PVH ¼ pulmonary venous hypertension; PVR ¼ pulmonary vascular resistance; RA ¼ right atrial; RV ¼ right ventricular; RVOT ¼ right ventricular outﬂow tract.
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1984precapillary PH, an elevated PADP-PCWP gradient
(i.e., diastolic pulmonary gradient) >5 to 7 mm Hg
has been advocated as the best way to diagnose true
combined pre- and post-capillary PH (i.e., PVH withsuperimposed precapillary PH) (30), as shown in
Figure 2.
DIAGNOSTIC EVALUATION OF THE RV. The RV plays
a central role in the diagnosis and management of PH.
FIGURE 3 Echocardiographic and CMR Evaluation of the RV in Pulmonary Hypertension
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(A) Right ventricular (RV) fractional area change; (B) tricuspid annular plane systolic excursion (TAPSE); (C) RV tissue Doppler longitudinal (s0)
velocity; (D) RV global longitudinal strain on speckle-tracking echocardiography; (E) late gadolinium enhancement of the RV insertion points on
cardiac magnetic resonance (CMR); and (F) “D-sign” of the left ventricle (LV) due to RV overload during peak inspiration on CMR. The central
image in the ﬁgure displays the superﬁcial muscle layer of the RV (dissection by Damian Sanchez-Quintana, University of Extremadura, Spain
[modiﬁed with permission from Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. Heart
2006;92 Suppl 1:i2-13]). CMR images courtesy of Benjamin Freed, MD, Northwestern University Feinberg School of Medicine. Ao ¼ aorta;
FAC ¼ fractional area change; ED ¼ end-diastole; ES ¼ end-systole; PT ¼ pulmonary trunk.
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1985In recent years, there has been increased focus on
evaluation of RV structure and function in the setting
of PH, using echocardiography and CMR as the 2 pri-
mary clinical imaging modalities. Table 2 lists use-
ful echocardiographic parameters for determiningwhether the RV is enlarged or dysfunctional.
RV systolic function can be evaluated using
2-dimensional images (e.g., RV fractional area chance
in the apical 4-chamber view) (Figure 3A); M-mode
(e.g., tricuspid annular plane systolic excursion
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1986[TAPSE]) (Figure 3B); and tissue Doppler imaging
(e.g., RV basal free wall systolic [s0] velocity at the
level of the tricuspid annulus) (Figure 3C) (41).
These techniques are easy to apply during routine
clinical echocardiography; however, RV fractional
area chance can be challenging to calculate when RV
images are suboptimal, and it is insensitive in cases of
subtle RV dysfunction; TAPSE and RV tissue Doppler
velocity are more sensitive indicators of RV dys-
function, but can be affected by M-mode or Doppler
beam misalignment, respectively, or by tethering to
the LV (i.e., if LV systolic function is hyperdynamic,
as is often the case in PAH, TAPSE and RV velocity can
be falsely elevated; alternatively, in patients with
severe LV systolic dysfunction, these measures can
be falsely low). Speckle-tracking echocardiography
(Figure 3D) allows for rapid assessment of RV
myocardial deformation (i.e., RV free wall strain) and
is not as angle-dependent.
CMR has the advantage of being a tomographic
technique that can provide 3-dimensional views of
the RV without being affected by acoustic window
quality. Thus, CMR provides the most accurate
noninvasive measurement of RV volumes, mass, and
ejection fraction. Gadolinium contrast injection dur-
ing CMR can be used to evaluate for focal RV ﬁbrosis;
patients with PAH often exhibit late gadolinium
enhancement at the RV insertion points (Figure 3E).
CMR cine images during inspiration can be very
helpful in understanding the ability of the RV to
handle volume overload. During inspiration, as in-
trathoracic pressure drops, blood is drawn into the
right heart from the systemic veins, ﬁlling the RA and
RV. Interventricular septal ﬂattening (“D sign”)
(Figure 3F) at peak inspiration is indicative of a
vulnerable or dysfunctional RV (in the absence of
an alternate etiology of septal ﬂattening, such as
constrictive pericarditis). In the future, novel imaging
techniques for the evaluation of diffuse RV ﬁbrosis,
RV metabolism, and RV perfusion will likely be pos-
sible and should further enhance our ability to un-
derstand RV pathophysiology in the setting of PH.
FURTHER TESTING FOR PATIENTS WITH PAH. In the
evaluation of patients with PH, if the diagnosis of
PVH has been established, the focus becomes left
heart disease, with further diagnostic measures de-
pending on the type of left heart lesion resulting in
elevated left atrial pressure. Alternatively, if the
initial diagnostic evaluation reveals pre-capillary PH,
further testing, including laboratory testing for HIV,
liver disease, and CTD; pulmonary function testing;
arterial blood gas analysis; ventilation-perfusion
scanning of the lung; chest computed tomography;and overnight polysomnography are helpful in clas-
sifying PH (1–3).
THERAPY FOR PAH
GENERAL MEASURES. Basic counseling and disease
state education are important components in the care
of PAH patients. Low-level graded aerobic exercise,
such as walking, is recommended. The beneﬁts of
intensive pulmonary rehabilitation have been dem-
onstrated (48). Patients are advised against heavy
physical exertion and isometric exercise, as this may
evoke exertional syncope. Oxygen supplementation
to keep saturation above 90% at rest and with
exertion, sleep, or altitude is advisable. A sodium-
restricted diet is advised and is particularly im-
portant to manage volume status in those with RV
failure. Routine immunizations, such as those against
inﬂuenza and pneumococcal pneumonia, are advised.
BACKGROUND THERAPY. Despite a paucity of data,
diuretic and anticoagulant agents are often appro-
priate therapies in PAH patients. Anticoagulant
agents have been studied in 4 uncontrolled observa-
tional series: 2 prospective and 2 retrospective, pri-
marily in IPAH patients (49–52). Improved survival
was observed in all 4 studies. Most guidelines rec-
ommend warfarin anticoagulation titrated to an in-
ternational normalized ratio of 1.5 to 2.5 in patients
with IPAH. One prospective registry also assessed
patients with associated forms of PAH and found no
beneﬁt of anticoagulation in such patients (52).
Diuretic agents are indicated to manage RV volume
overload. Occasionally, intravenous (IV) diuretic
agents are required. Serum electrolytes and renal
function should be followed closely. There are few
data pertaining to digoxin, although it is sometimes
used in patients with right heart failure and low car-
diac output and in those with atrial arrhythmias.
CALCIUM-CHANNELBLOCKERS. Calcium-channel blockers
can be a very effective treatment for those few patients
with an acute response to vasodilator testing as outlined
in the previous text. Patients who meet criteria for a
positive vasodilator response can be treated with a
calcium-channel blocker, but should be followed
closely for both safety and efﬁcacy of therapy. If a pa-
tient meeting the deﬁnition of an acute response does
not improve to functional class I or II on calcium-
channel blockers, an alternative PAH-speciﬁc therapy
should be prescribed. Very few patients (<7%) with IPAH
do well over the long-term on calcium-channel blockers
(43). Long-acting nifedipine, diltiazem, and amlodipine
are the most commonly-used agents. Due to its potential
for negative inotropic effects, verapamil should be
avoided.
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1987PROSTACYCLINS. Prostacyclin synthase expression
is reduced in endothelial cells from PAH patients,
resulting in inadequate production of prostaglandin I2
(i.e., prostacyclin), a vasodilator with antiproliferative
effects (53). Administering prostanoids has been a
mainstay of PAH therapy for nearly 2 decades. There
are currently multiple prostanoids commercially
available: epoprostenol (continuous IV), treprostinil
(continuous subcutaneous, continuous IV, intermit-
tent inhaled, and oral) and iloprost (intermittent
inhaled). Prostanoids are complex therapies and are
best administered by a center with expertise in the
complicated delivery systems and chronic manage-
ment of side effects and dosing.
Epoprostenol was the ﬁrst therapy approved by the
FDA for IPAH. Randomized controlled clinical trials in
IPAH demonstrated improvements in exercise toler-
ance, as measured by the 6MWD, hemodynamics,
quality of life, and survival over a 12-week period
(54). Long-term observational series have also sug-
gested improved survival on IV epoprostenol (55,56).
IV epoprostenol has also been evaluated in PAH
related to the scleroderma spectrum of diseases, with
improvements in 6MWD and hemodynamics demon-
strated by a 12-week randomized controlled clinical
trial in this population (57). Observational series have
also reported favorable effects of IV epoprostenol in
patients with additional forms of associated PAH.
Epoprostenol must be delivered by continuous IV
infusion. Each patient must learn the techniques of
sterile preparation of the medication, operation of
the ambulatory infusion pump, and care of the central
venous catheter. More recently, a thermostable for-
mulation of epoprostenol, which does not require ice
packs and can be mixed less frequently, has been
approved. Intravenous epoprostenol is commonly
started in the hospital at a dose of 2 ng/kg/min and
up-titrated, depending on symptoms of PAH and side
effects of the therapy. Although dosing is highly
individualized, the optimal dose for most adult pa-
tients tends to be in the range of 25 to 40 ng/kg/min.
Common side effects include jaw pain, ﬂushing,
nausea, diarrhea, skin rash, and musculoskeletal
pain. Infections and infusion interruptions can be
life-threatening.
Treprostinil is a prostanoid currently approved as a
continuous subcutaneous infusion, continuous IV
infusion, or an intermittent inhaled treatment. Tre-
prostinil was ﬁrst studied as a subcutaneous infusion
in a placebo-controlled, multicenter randomized trial
of 470 patients over 12 weeks (58). There was a dose-
related improvement in 6MWD of 16 m. Adverse ef-
fects included pain and erythema at the site of the
subcutaneous infusion in 85% of patients. Othercommon side effects included headache, diarrhea,
rash, and nausea. On the basis of bioequivalence data,
treprostinil is FDA-approved for a continuous IV de-
livery. Treprostinil has been approved for intermit-
tent inhaled use. In a multicenter, randomized,
placebo-controlled study of 235 PAH patients who
were still symptomatic despite oral bosentan or sil-
denaﬁl therapy, the addition of inhaled treprostinil
resulted in an improvement in the primary endpoint
of 6MWD (59). Common side effects included cough,
headache, nausea, dizziness, and ﬂushing.
Treprostinil diethanolamine is a salt form of tre-
prostinil designed to release the drug in a sustained-
release osmotic tablet for twice daily dosing. Oral
treprostinil has been studied as monotherapy in 349
PAH patients over 12 weeks (60). An improvement of
23 m (p ¼ 0.0125) in the primary endpoint of 6MWD
was observed. There were no improvements in the
secondary endpoints of time to clinical worsening or
functional class. The most common adverse events
were headache, nausea, diarrhea, and jaw pain. Oral
treprostinil has also been studied in 2 randomized
controlled trials as add-on therapy to endothelin re-
ceptor antagonists and/or phosphodiesterase type 5
(PDE-5) inhibitors (61,62). The primary endpoint of
6MWD was not improved in either trial. The FDA
approved oral treprostinil in December 2013 to
improve exercise capacity, noting that the drug did
not offer additional beneﬁt when added to other
vasodilator therapy in 2 16-week double blind,
placebo-controlled trials.
A 12-weekmulticenter, randomized,placebo-controlled
trial in 207 patients of iloprost, an inhaled prostanoid,
demonstrated an improvement in a novel composite
endpoint that included an improvement by at least 1 level
of functional class, improvement in 6MWD by at least
10%, and the absence of clinical deterioration (63). Inhaled
iloprost has also been studied in combination with
bosentan in a multicenter, randomized, placebo-
controlled trial. After 12 weeks, there were improvements
in functional class and time to clinical worsening. The
combination appeared to be safe. Common side effects of
inhaled iloprost include cough, headache, ﬂushing, and
jaw pain.
ORAL PAH-SPECIFIC THERAPIES. Endothel in pathway .
Increased tissue expression and increased plasma levels
of endothelin-1, a potent vasoconstrictor and stimulator
of cell proliferation, have been described in PAH, high-
lighting the potential of targeting this pathway in the
treatment of PAH. Endothelin receptor antagonists act by
selectively blocking endothelin-A receptors or by dual
blockage of endothelin-A and -B receptors; furthermore,
theyconstituted theﬁrst classofdrugsorallyadministered
in PAH (64–66).
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1988Bosentan, a nonselective endothelin-A and -B
receptor antagonist has been studied in multiple
placebo-controlled trials in PAH. The BREATHE-1
study, a multicenter, randomized, placebo-controlled
trial of 213 functional class III and IV PAH patients
demonstrated an improvement in 6MWD and the
composite endpoint of time to clinical worsening
over 16 weeks (67). More recently, bosentan has
been evaluated in functional class II patients in a
6-monthmulticenter, randomized, placebo-controlled
trial (68). This study demonstrated an improvement
in PVR and time to clinical worsening. The
improvement in 6MWD was not statistically signiﬁ-
cant. Bosentan has been studied speciﬁcally in pa-
tients with congenital systemic to pulmonary shunts
and Eisenmenger physiology (69). In this population,
improvements in PVR, mPAP, and 6MWD were
noted, and bosentan did not worsen oxygen satura-
tion. Bosentan is currently widely used in patients
with PAH. Close follow-up of both efﬁcacy and
safety is encouraged. The FDA requires liver func-
tion to be checked on a monthly basis, and an
algorithm for managing elevated liver function tests
is available in the package insert. Other side effects
include headache, anemia, and edema.
Ambrisentan, a selective endothelin-A receptor
antagonist, has been studied in 2 phase III multi-
center, randomized, placebo-controlled trials in 394
PAH patients and demonstrated an improvement
in 6MWD and time to clinical worsening (70). The FDA
no longer requires monthly liver function test moni-
toring in patients on ambrisentan, although many
experts continue to check liver function periodically.
Other side effects of ambrisentan include ﬂuid
retention, nasal congestion, ﬂushing, and anemia.
Macitentan, a nonselective endothelin-A and -B
receptor antagonist, has increased tissue penetration
and more sustained receptor blockade compared with
bosentan (71). It has been studied in a phase III long-
term morbidity and mortality trial (n ¼ 742) in which
the primary endpoint was the time from initiation of
treatment to the ﬁrst occurrence of a composite
endpoint of death, atrial septostomy, lung trans-
plantation, initiation of treatment with parenteral
prostanoids, or worsening PAH (72). Patients were
randomized to either placebo or macitentan 3 or 10
mg daily. There were 30% and 45% risk reductions in
the primary endpoint with the 3- and 10-mg doses,
respectively. Both patients on PAH-speciﬁc therapy
(such as PDE5 inhibitors) and treatment-naïve
patients had improvements in the primary and
secondary outcome measures. The most frequent
adverse events were headache, nasopharyngitis, and
anemia. The incidence of edema and elevation ofliver function tests were similar in the placebo and
macitentan groups. Macitentan was FDA-approved to
delay disease progression, including death, initiation
of prostanoid therapy, or clinical worsening in
PAH. Unlike bosentan, monthly liver function test
monitoring is not required, although physicians are
encouraged to monitor as clinically indicated.
Nitr i c ox ide pathway. Nitric oxide (NO) is a potent
vasodilator of the pulmonary circulation, acting
through the increase in cyclic guanosine mono-
phosphate (cGMP), and cleared mainly as a result of
degradation by PDE-5. Reduction in the expression of
NO synthase has been described as a mechanism
associated with the pathogenesis of PH (73).
Currently, there are 2 therapeutic classes of drugs
interacting in the NO pathway, aiming to increase
the direct action of cGMP: PDE-5 inhibitors, which
decrease cGMP degradation, and soluble guanylate
cyclase stimulators, which increase cGMP production.
Phosphodiesterase type 5 inhibitors. Sildenaﬁl has
been studied in a 12-week multicenter, randomized,
placebo-controlled trial and was found to improve
6MWD and hemodynamics, but not the secondary
endpoint of time to clinical worsening (74). The
improvement was not dose-related, and sildenaﬁl
is currently approved at a dose of 20 mg 3 times a
day. More recently, tadalaﬁl was studied in a 16-
week multicenter, randomized, placebo-controlled
trial and demonstrated an improvement in the
primary endpoint of 6MWD (75). The highest dose
studied (40 mg) also resulted in an improvement
in the secondary endpoint of time to clinical
worsening. Tadalaﬁl is approved at a dose of 40 mg
once daily. The most common side effects of
the PDE-5 inhibitors include headache, ﬂushing,
dyspepsia, myalgias, and epistaxis.
Soluble guanylate cyclase stimulators. Riociguat is a
ﬁrst-in-class soluble guanylate cyclase stimulator.
It directly stimulates soluble guanylate cyclase
independent of nitric oxide, and increases the
sensitivity of soluble guanylate cyclase to nitric oxide
(76,77). A randomized controlled trial of 261 patients
with either inoperable CTEPH or persistent PH
after pulmonary endarterectomy demonstrated an
improvement in the primary endpoint of 6MWD
and the secondary endpoints of PVR, N-terminal pro–
B-type natriuretic peptide (BNP), and functional class
with riociguat (78). A randomized controlled trial
of 443 PAH patients (44% previously treated with
endothelin receptor antagonists and 6% with
nonparenteral prostanoids) also demonstrated an
improvement in the primary endpoint of 6MWD as
well as multiple secondary endpoints including PVR,
N-terminal proBNP, functional class, and time to
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1989clinical worsening with riociguat (79). The most
common adverse events included syncope, headache,
dyspepsia, peripheral edema, and hypotension.
Cases of hemoptysis have also been reported.
Concomitant use of riociguat and PDE-5 inhibitors
is contraindicated due to hypotension. The FDA
approved riociguat to improve exercise capacity,
functional class, and delay in clinical worsening in
group 1 PAH and to improve exercise capacity and
functional class in patients with persistent PH after
surgical pulmonary endarterectomy, or for those
with inoperable CTEPH. It must be emphasized
that patients with surgically-accessible CTEPH are
best treated with surgery, and should not receive
riociguat instead of pulmonary endarterectomy.
LUNG TRANSPLANTATION AND BRIDGE TO
TRANSPLANTATION WITH EXTRACORPOREAL LIFE
SUPPORT. Despite recent advances in medical ther-
apy, lung and heart-lung transplantation remains an
essential treatment option for PAH patients in the
modern management era (80–83). It is widely recog-
nized that transplant referral should occur before the
patient develops severe RV failure and that eligible
patients should be counseled about lung transplant
early in their diagnosis (83). Due to limited organ
availability and high mortality rates while awaiting
transplantation, eligible patients who are in NYHA
functional class III or IV symptoms with other clinical,
and/or hemodynamic predictors of poor prognosis on
best standard of care including a parenteral prosta-
cyclin have to be considered for lung transplantation.
The same applies for eligible patients initially pre-
senting with end-stage PAH in NYHA functional class
IV. Bilateral sequential lung transplantation is the
most common procedure. However, practice may
vary from center to center, and heart-lung trans-
plantation may be required for some patients in the
context of complex Eisenmenger physiology and is
also preferred by some centers in the setting of re-
fractory RV failure. Although some patients with
PVOD may respond to low-dose PAH therapy, many
will have no response or will deteriorate with such
therapy. Thus, PVOD patients should be managed
with lung transplant teams to offer a timely listing of
lung transplant candidates.
It is important to identify patients with persistent
evidence of RV failure in the presence of maximal
medical treatment before they develop irreversible
end-organ injury. If appropriate, these patients
should be considered for bridging to lung trans-
plantation (80–83). Indeed, circulatory support may
allow stabilization of patients, with improvement in
organ function and increased probability of survival.
Extracorporeal life support should thus beconsidered in PAH patients in the setting of persistent
RV failure despite optimal medical management.
Bridge therapy should be discussed and initiated
earlier in the course of RV failure, before the occur-
rence of secondary organ injury. Parameters known to
be associated with high mortality in PAH patients
requiring inotropic support include systemic hypo-
tension, elevated creatinine, hyponatremia, high
BNP levels, and increasing inotrope requirements.
Because of life-threatening RV failure, extracorporeal
life support should support the heart without
compromising oxygenation. Both the pulmonary ar-
tery–left atrium Novalung (Xenios AG, Heilbronn,
Germany) and venoarterial extracorporeal membrane
oxygenator have been used to bridge PAH patients for
several weeks until transplant (80,82). One must bear
in mind that extracorporeal life support complica-
tions can be serious (e.g., infection at the cannulation
site, hemorrhage, renal failure, neurologic complica-
tions, vascular access site injury, thromboembolic
complications), emphasizing the need for these pro-
cedures to be performed in well-selected patients
treated in experienced centers (80,82). Of note, lung
transplantation is a life-saving procedure in severe
PAH with survival rates after 1, 5, 10, and 15 years of
70%, 50%, 39% and 26% (heart-lung transplantation)
and 79%, 52%, 43%, and 30% (double-lung trans-
plantation), respectively (81).
ATRIAL SEPTOSTOMY. Balloon atrial septostomy
(artiﬁcial creation of a right-to-left shunt to decom-
press the right heart) can be performed percutane-
ously with careful graded balloon dilation. This
approach has been proposed by some experienced
centers to improve peripheral oxygen delivery, de-
spite a fall in systemic arterial saturation due to a
compensatory rise in cardiac output. Balloon atrial
septostomy has a high periprocedural mortality in
patients with markedly elevated right atrial pressure
and should only be considered as a palliative therapy
or bridge to transplantation in centers with experi-
ence in this procedure (84).
APPROACH TO THERAPY. The optimal therapeutic
approach must be individualized for every patient,
taking into account many factors including the
severity of illness, route of administration of therapy,
side effect proﬁle, comorbid illnesses, treatment
goals, and clinician experience and preference. Some
of the factors that place patients at highest risk are
listed in Table 3. Aggressive upfront triple combina-
tion therapy may be considered in the most seriously
ill patients upon presentation (85). Emerging evi-
dence favoring upfront dual oral combination therapy
with tadalaﬁl and ambrisentan in treatment-naïve
TABLE 3 High Risk Factors
Syncope Yes
NYHA/WHO class IV
6MWD <300 m
CPET Peak oxygen uptake <12 ml/kg/min
Echocardiographic ﬁndings Pericardial effusion
TAPSE <1.5 cm
Hemodynamics RAP >15 mm Hg
Cardiac index #2 l/min/m2
CMR RVEF <35%
CMR ¼ cardiac magnetic resonance; CPET ¼ cardiopulmonary exercise testing;
NYHA ¼ New York Heart Association; RAP ¼ right atrial pressure; RVEF ¼ right
ventricular ejection fraction; TAPSE ¼ tricuspid annular plane systolic excursion;
WHO ¼ World Health Organization; 6MWD ¼ 6-min walking distance.
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common treatment strategy currently employed is
goal-oriented sequential combination therapy. Al-
though the primarily observational studies described
previously do not allow for deﬁnitive conclusions,
reasonable goals of therapy include (86):
 Modiﬁed NYHA functional class (World Health Or-
ganization functional class): I or II
 Echocardiography/CMR: normal or near-normal RV
size and function
 Hemodynamics: normal indexes of RV function
(right atrial pressure <8 mm Hg and cardiac index
>2.5 to 3.0 l/min/m2)
 6MWD >380 to 440 m
 Cardiopulmonary exercise testing: peak oxygen
uptake >15 ml/min/kg and ventilatory equivalents
for CO2 <45 l/min
 BNP level: “normal” (determined by local labora-
tory cutoff values)
Over the years, many treatment approaches have
been published, including those put forth at the 5th
World Symposium on PH and by the American College
of Chest Physicians (87,88). Our proposed treatment
algorithm is depicted in the Central Illustration.
FUTURE DIRECTIONS
Oral selexipag is a pulmonary vasodilator that acts
on the human prostaglandin I2 (IP) receptor. The ef-
ﬁcacy of selexipag has been tested in multicenter,
randomized controlled trials, including a recently-
completed large, phase III, double-blind, placebo-
controlled, event-driven, morbidity and mortality
trial that enrolled 1,156 PAH patients. In that study,
selexipag signiﬁcantly decreased the risk of a
morbidity/mortality event versus placebo by 43%
(p < 0.0001) (89). Results of this trial were presentedMarch 15, 2015, at the ACC. 15 in San Diego,
California (90).
The importance of growth factors in pulmonary
vascular remodeling suggests that receptor tyrosine
kinase inhibition could be an interesting anti-
proliferative approach in PAH. The IMPRES (Imatinib
in Pulmonary Arterial Hypertension, a Randomized,
Efﬁcacy Study) study showed that imatinib therapy
could improve cardiac output with a modest reduc-
tion in mPAP in a patient population with advanced
disease despite therapy with at least 2 PAH drugs (91).
However, the unfavorable risk-beneﬁt proﬁle of
imatinib has resulted in cessation of its further ther-
apeutic development in PAH, and its off-label use in
PAH is not encouraged. Targeting growth factors,
however, remains an attractive strategy in PAH, but a
better understanding of this treatment approach will
be required to facilitate the development of new
drugs that could block proliferative pathways without
severe side effects.
Serotonin causes pulmonary artery vasoconstric-
tion and pulmonary artery smooth muscle cell pro-
liferation. Terguride, a 5HT-2 receptor antagonist,
was not efﬁcacious in either hemodynamics or exer-
cise capacity in a phase II trial. De novo synthesis of
serotonin from tryptophan is catalyzed by tryptophan
hydroxylase-1 (TPH-1) and overexpression of the
TPH-1 gene has been found in remodeled arteries of
PAH patients. Moreover, hypoxic PH is attenuated in
TPH-1 knockout mice. Thus, inhibition of TPH-1 is
a potential target against the serotonin system in
PAH (83,92).
Rho-kinase is the downstream effector of the small
GTPase, RhoA, and mediates a range of cellular
functions such as cell migration and smooth muscle
contraction. Fasudil is a potent Rho-kinase inhibitor,
and acute IV administration has led to a 17% reduc-
tion in PVR in a small observation study of 9 PAH
patients. A long-acting oral formulation of fasudil was
recently tested in a pilot randomized controlled trial
in Japan involving 23 PAH patients over 12 weeks. No
signiﬁcant differences in pulmonary hemodynamics
and 6MWD were seen between the 2 groups at the end
of the study. Pulmonary edema and pleural effusions
occurred in 1 patient treated with fasudil, resulting in
death, and a causal relationship with the drug could
not be excluded (93).
A link between inﬂammation and PAH patho-
genesis is supported by several clinical and pre-
clinical observations. Anti-inﬂammatory therapies
have been explored predominantly in CTD-associated
PAH, and small case series have reported clinical
response to immunosuppression using a combination
of cyclophosphamide with glucocorticoids. However,
CENTRAL ILLUSTRATION Treatment Algorithm for PAH
Does IPAH patient have a positive response to acute pulmonary vasodilator testing?
(Decrease in mean pulmonary arterial pressure [mPAP] to 40 mm Hg; Decrease in mPAP by 10 mm Hg; and Unchanged or increased cardiac output)
Does patient improve to functional class I or II 
with sustained hemodynamics benefits?
Continue with CCBs
with careful monitoring
* Initial combination of 
ambrisentan and tadalafil is 
superior than ambrisentan or 
tadalafil alone (in functional 
class II and III PAH patients)
Highest-risk patients are 
underrepresented in 
randomized controlled trials; 
Expert opinion favors upfront 
combination of 2 to 3 drugs, 
including epoprostenol
Prescribe calcium-channel blockers (CCBs) 
Patient with suspected pulmonary hypertension (PH)
Diagnostic evaluation to identify pulmonary arterial hypertension (PAH) patients: Echocardiography (to evaluate cardiac causes of PH), 
PFT, V/Q scan, CT scan, invasive hemodynamic testing (careful cardiac catheterization), and laboratory testing (ANA, LFTs, HIV)
Vasoreactivity challenge for idiopathic, heritable, and anorexigen-induced PAH patients in functional class I, II, or III
to help determine which patients are more likely to be long-term responders to calcium-channel-blockers (CCBs)DI
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Is the patient of higher risk?
If inadequate response, consider referral to lung transplant or balloon atrial septostomy (BAS)
Pulmonary arterial specific therapy:
Endothelin receptor antagonist (ERA)
Phosphodiesterase type 5 inhibitor (PDE5i)
Soluble guanylate cyclase stimulator (sGC)
Prostanoids (treprostinil, iloprost)
Epoprostenol
Upfront Combination therapy*
Pulmonary arterial specific therapy:
Epoprostenol
Upfront Combination therapy*
Endothelin receptor antagonist (ERA)
Phosphodiesterase type 5 inhibitor (PDE5i)
Soluble guanylate cyclase stimulator (sGC)
Prostanoids (treprostinil, iloprost)
Consider referral to lung transplant
If inadequate response (according to predefined treatment goals), sequential combination therapy:
ERA +/- PDE5i or sGC +/- prostanoids or epoprostenol. Consider clinical trials and/or referral for lung transplant
Consider
clinical
trials in 
appropriate
patients
Y N
Y N
NY
McLaughlin, V.V. et al. J Am Coll Cardiol. 2015; 65(18):1976–97.
ANA ¼ antinuclear antibody; BAS ¼ balloon atrial septostomy; CCB ¼ calcium-channel blockers; CT ¼ computed tomography; ERA ¼ endothelin receptor antagonist;
HIV ¼ human immunodeﬁciency virus; IPAH ¼ idiopathic pulmonary hypertension; LFT ¼ liver function test; mPAP ¼ mean pulmonary arterial pressure; PAH ¼ pul-
monary arterial hypertension; PDE5i ¼ phosphodiesterase type 5 inhibitor; PFT ¼ pulmonary function tests; PH ¼ pulmonary hypertension; sGC ¼ soluble guanylate
cyclase stimulator; V/Q ¼ ventilation perfusion scan.
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1992beneﬁcial effects are restricted to PAH that is associ-
ated with systemic lupus erythematosus and mixed
connective tissue disorders (CTD), but not in
scleroderma, the most common CTD associated with
PAH (94). A phase II study investigating B-cell
depletion with rituximab (monoclonal antibody
against CD20) in scleroderma-associated PAH is under-
way (NCT01086540) (95).
Mitochondrial abnormalities with a metabolic
switch favoring cytosolic glycolysis, rather than
normal mitochondrial aerobic metabolism, have been
demonstrated in PAH. Such metabolic abnormalities
can be partially corrected by the agent dichlor-
oacetate, which has been shown to reverse PH in
animal models (96). A phase I open-label trial is
currently investigating dichloroacetate in PAH
(NCT01083524) (97).
The leading cause of heritable PAH is germline
mutations in BMPR2. Moreover, the ﬁnding that
BMPR2 function is also reduced in IPAH has led to
major interest in restoring BMPR2 function in PAH
patients. Interestingly, gene transfer of BMPR2 using
adenovirus vector has been shown to improve PH
induced by hypoxia and monocrotaline in rats. Using
a transcriptional high-throughput luciferase reporter
assay, the calcineurin inhibitor FK506 (tacrolimus)
was recently found to be a candidate compound that
can up-regulate BMPR2 signaling. Low-dose FK506
also reverses both hypoxic and monocrotaline forms
of experimental PH (98).
Endothelial progenitor cells are bone marrow–
derived progenitor cells involved in vascular ho-
meostasis, which can circulate, proliferate, and
differentiate into mature endothelial cells at sites of
vascular injury. A study of autologous transplantation
of ex vivo cultured endothelial progenitor cells
has showed interesting short-term results in 31 PAH
patients (99). Since this initial proof-of-concept
study, no further human trials in adults have been
published.
As observed in congestive heart failure, PAH is
associated with neurohormonal activation, as evi-
denced by increased sympathetic nerve trafﬁc and
up-regulation of the renin-angiotensin-aldosterone
system. Interestingly, plasma levels of renin and
angiotensin I and II are increased in PAH and have been
associated with worse prognosis (100). In addition,
b-blockers, acetylcholinesterase (ACE) inhibitors,
angiotensin-II receptor blockers, and aldosterone an-
tagonists have produced beneﬁcial hemodynamic ef-
fects in experimental PH (101). In clinical practice,
aldosterone antagonists are already widely used in the
treatment of RV failure. In contrast, there is limited
data to support the use of b-blockers in PAH, andextreme caution is advocated due to reported symp-
tom worsening with b-blocker administration.
Pulmonary artery denervation has recently been
proposed for PAH in an attempt to abolish sympa-
thetic nerve supply to the pulmonary circulation. In
a ﬁrst-in-human single-center proof-of-mechanism
study, 13 patients underwent this procedure with
a dedicated radiofrequency ablation catheter. This
investigational approach resulted in signiﬁcant im-
provement of mPAP and 6MWD, but requires further
conﬁrmation (102).
Potts shunt is a surgical method of RV decom-
pression via the creation of an anastomosis between
the descending aorta and left pulmonary artery. In
case of suprasystemic PH, an advantage of Potts
shunt over atrial septostomy is the sparing of the
cerebral and coronary circulation from deoxygenated
blood (103). Recently, an investigational small case
series of adults with NYHA functional class IV PAH
demonstrated the feasibility of creating a Potts shunt
via an interventional percutaneous approach (104).
SPECIAL SITUATIONS INCLUDING
PERIOPERATIVE CARE, PREGNANCY,
AND ICU CARE
PERI-OPERATIVE CARE. Patients with signiﬁcant PAH
are at high risk for general anesthesia. Perioperative
risk was studied in an international prospective 3-year
questionnaire-based survey among 11 PH centers
(105). Major complications occurred in about 6% of
patients, and overall perioperative mortality was
about 3.5%. The factors that increased complications
and mortality were more advanced disease, man-
ifested by a higher right atrial pressure and a lower
6MWD. The need for emergency surgery and the use
of perioperative vasopressors also increased risk.
PAH can be considered a ﬁxed obstructive cardio-
pulmonary lesion with intraoperative physiology
similar to severe aortic or mitral stenosis. During in-
duction of anesthesia, systemic vasodilation is com-
mon, and systemic blood pressure can decrease.
Systemic hypotension can exacerbate RV ischemia by
decreasing the right coronary artery perfusion pres-
sure during systole, resulting in decreased cardiac
output due to worsening RV function. The reduction
in pulmonary blood ﬂow results in more underﬁlling
of the LA and LV, worsening the systemic hypo-
tension. Furthermore, as the LV becomes more
underﬁlled and the RV becomes more overloaded,
increased interventricular septal ﬂattening ensues,
further decreasing the ability of the LV to ﬁll. These
abnormalities can quickly result in acute decompen-
sation and potential death in a patient with PAH.
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with PAH, the following strategies can help to ensure
the best outcome perioperatively: 1) if possible, try to
avoid general anesthesia (e.g., use a nerve block);
2) evaluate and treat for decompensated right heart
failure; 3) in patients with severe PAH (e.g., those
with functional class III or IV symptoms, or on IV or
subcutaneous prostacyclins), perform pre-operative
right heart catheterization and optimize hemody-
namics prior to elective surgery; and 4) in the oper-
ating room, have available PA catheter monitoring,
transesophageal echocardiography, and inhaled nitric
oxide. All PAH patients should continue vasodilator
medications perioperatively, and a PAH specialist
should be involved in perioperative management,
especially in high-risk PAH patients who are on
advanced prostanoid therapies.
PREGNANCY. Despite the advent of multiple classes
of medications for PAH patients, pregnancy is con-
traindicated in these patients. Although there is not
much controlled data on pregnancy in PAH, a sys-
temic review of case reports demonstrated a very
high 30% to 56% mortality in PAH during pregnancy
or in the early post-partum period (106). Bonnin et al.
(107) found a maternal mortality rate of 36% in a se-
ries of 15 consecutive PAH patients who became
pregnant in the modern era of PAH treatment. A more
contemporary description is of 26 pregnancies in PAH
patients at 13 PAH centers (108). There were 3 deaths
(12%), and 1 patient developed refractory right heart
failure and underwent heart-lung transplantation
post-partum. There were 2 spontaneous and 6 in-
duced abortions. Overall, 62% of the pregnancies
resulted in a healthy baby without maternal compli-
cations. These women had well-controlled PAH
(mean PVR 500  352 dynes/s/cm5). One-half were
long-term calcium-channel blocker responders.
Several normal physiological changes in pregnancy
can be deleterious to the patient with PAH, particu-
larly the increase in blood volume and requirement
for increased cardiac output, along with systemic
vasodilation. As with other types of ﬁxed obstructive
lesions (such as aortic and mitral stenosis), pregnancy
is poorly tolerated in patients with PAH. Further-
more, certain pulmonary vasodilators, such as the
endothelin receptor antagonists, are contraindicated
in pregnancy because of teratogenicity. Thus, all fe-
male patients with PH, particularly PAH, should avoid
pregnancy, and contraception should be used in
sexually-active patients (1).
Despite warnings and contraceptive measures to
avoid pregnancy, some women with PAH will get
pregnant. In these patients, termination of pregnancyshould be discussed. If the patient desires to keep the
pregnancy, the following steps should be followed to
try to ensure the best possible outcome for the
mother and child: 1) referral to a PAH specialist and
high-risk obstetrician (with close collaboration be-
tween the PAH and obstetrics teams); 2) discontinue
endothelin receptor antagonists immediately (cate-
gory X) in patients who are taking them; 3) maintain
patients on anticoagulation (low molecular-weight
heparin), oxygen, and diuretic agents; 4) continue
PDE5 inhibitors and prostacyclins (category B), and
in patients with signiﬁcant PAH who are not yet
on prostacyclin therapy, initiation of such ther-
apy should be considered; 5) close follow-up with
monthly visits and echocardiograms to screen for and
treat RV decompensation and right heart failure; and
6) perform elective, planned delivery with Caesarean
section and spinal-epidural anesthesia (at 34 weeks
of gestation, if possible) (1,107).
INTENSIVE CARE UNIT MANAGEMENT. With ad-
vances in pharmacological therapy for PAH, many
patients can now survive with good functional status.
However, the RV remains vulnerable in these pa-
tients, and they can quickly spiral downward in the
setting of stressors, such as infection, medication,
and/or dietary noncompliance, and become critically
ill. Unfortunately, there is scant evidence for the
appropriate management of PAH patients in the
intensive care unit, and expert consensus is the pri-
mary basis of treatment guidelines (80).
Management of the RV is central to successfully
treating PAH patients who are critically ill. Often,
clinicians have a knee-jerk reaction to give ﬂuids to
patients with sepsis or hypotension, a management
strategy that can have dire consequences in the
setting of PAH. For example, in a patient with PAH
who is septic or has a severe infection, systemic
vasodilation occurs. As outlined earlier in describing
the hemodynamic reaction to general anesthesia, the
RV can become more ischemic due to decreased RV
perfusion, resulting in further exacerbation of sys-
temic hypotension due to decreased cardiac output.
The RV enlarges and compresses the LV, further
decreasing LV ﬁlling. In this setting, administration
of IV ﬂuids will only compound the problem as RV
diastolic pressure rises (further impeding right coro-
nary blood ﬂow), and interventricular septal ﬂat-
tening will worsen.
It is also important to note that acute-on-chronic
RV failure in PAH is physiologically different than
acute RV failure (e.g., RV myocardial infarction).
Most PAH patients are not pre-load–dependent in
the setting of RV failure, and even small boluses of IV
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1994ﬂuid can be very harmful. Finally, renal venous
congestion often occurs in patients with PAH who are
critically ill with RV failure. RA pressure (and there-
fore central venous pressure) is high in decom-
pensated PAH, resulting in increased renal venous
pressure, and systemic hypotension decreases renal
perfusion. These hemodynamic changes decrease
renal blood ﬂow and result in increased ﬂuid
retention.
Given these hemodynamic abnormalities, we
advocate the following steps for the management of
critically ill PAH patients: 1) consider invasive he-
modynamic monitoring (e.g., pulmonary artery cath-
eter) for diagnostic purposes to determine the
hemodynamic abnormality and ﬁlling pressures pre-
sent; 2) increase systemic blood pressure with drugs
such as dobutamine and/or phenylephrine to achieve
a systolic blood pressure >90 mm Hg; 3) optimize
central venous pressure to 8 to 10 mm Hg (use IV
diuretic agents, ultraﬁltration, or continuous veno-
venous hemoﬁltration if necessary); 4) transfuse
packed red blood cells to maintain hemoglobin
>10 g/dl; 5) continue pulmonary vasodilator drugs
that the patient was taking previously as an outpa-
tient; and 6) consider prescribing iNO (typical dose ¼
20 ppm), especially if the patient is on a ventilator,
remembering to wean off slowly to avoid rebound
elevations in PA pressure. If these measures fail,
adding an inotropic agent to increase RV contractility
can be considered. In addition, the use of short-term,
percutaneous, partial ventricular support devices,
such as a Tandem Heart (CardiacAssist, Inc., Pitts-
burgh, Pennsylvania) (inﬂow cannula in the RA and
outﬂow cannula in the PA) or RV Impella catheter
(Abiomed, Danvers, Massachusetts) have been des-
cribed in the setting of RV failure (109,110). In severe
cases, where there is a clear reversible cause of RV
decompensation, extracorporeal life support (e.g.,
venoarterial extracorporeal membrane oxygenator)
can be administered and can be life-saving; bilateral
lung transplantation should also be considered in
these cases (80).
COLLABORATIVE CARE OF THE PAH PATIENT.
Management of the PAH patient requires a multidis-
ciplinary approach and collaboration between local
care and the PH specialty center (Figure 4). Given the
delay from symptom onset to diagnosis, greater
awareness in the community is required to achieve
earlier diagnosis. Some community settings may be
equipped to perform a thorough diagnostic evalua-
tion, including a right heart catheterization with
vasodilator testing, whereas others may not. An open
dialogue with a PH center will help facilitate a correctand timely diagnosis in instances where local exper-
tise is not available.
Given the complexities of the diagnosis and the
cost and side effect proﬁle of the therapies, referral to
a PH center to conﬁrm the diagnosis and comanage
the patient should be considered. A recent series
describing new referrals to 3 PH specialty centers
demonstrated that patients are referred late, with
functional class 3 and 4 symptoms, more than one-
half of the time; the diagnosis is often incorrect
(nearly one-half of patients receive a different diag-
nosis after evaluation at the referral center); and
PAH-speciﬁc therapy is commonly started inappro-
priately (111). In fact, 30% of patients received PAH-
speciﬁc therapies before referral, and 57% of the
time the use of PAH-speciﬁc therapy was not in
accordance with PH guidelines.
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that is not available in the community. PH nurse cli-
nicians are critical in the management of PAH pa-
tients. They provide vital education regarding the
disease and its therapies, and maintain an active role
in case management to titrate medications, monitor
side effects, and recognize complications. Access to
clinical research trials and advanced treatment op-
tions, such as parenteral prostacyclins and lung or
heart-lung transplantation, are important aspects of
care available at PH centers.
Collaboration is key, and it is incumbent upon the
PH center to maintain an open dialogue with local
health care providers. The primary care physician or
local cardiologist or pulmonologist must be kept up to
date on the patient’s status and therapies, as they
may be the ﬁrst physician to encounter a complica-
tion of PAH therapy (e.g., a line infection), to recog-
nize disease progression (e.g., ﬂuid retention and
right heart failure), or to diagnose a new problem
(e.g., pneumonia). As many patients live far from the
PH center, comanagement of such issues is in the
patient’s best interest.CONCLUSIONS
Over recent decades, many advances have led to a
better understanding of and treatment for PAH. It is
critical that the appropriate diagnosis be made in
a timely fashion. Differentiating PAH from PVH
is important and requires a thorough evaluation.
Numerous therapies are available to treat PAH, and
an aggressive approach targeting multiple pathways
may lead to better outcomes. The health of the RV is
the key determinant of prognosis; despite advances
in the treatment of PAH, management of RV failure
remains suboptimal for many patients. Fortunately,
this remains an area of active research with oppor-
tunities for translational discoveries that have the
potential to improve patient care.
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